Targets › CFI
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Sep 2028.
Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. (UniProt, P05156)
Open in Phaseline: the race on CFI, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Purespring Therapeutics | PS-002 Adeno-associated viral vector delivering Complement Factor I (CFI) gene to correct complem | CFI | Phase 1 | Immunoglobulin A (IgA) Nephropathy | Sep 2028 |
Immunoglobulin A (IgA) Nephropathy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.